Navidea Biopharmaceuticals (NAVB) Earnings Date, Estimates & Call Transcripts → Charles Payne Demystifies Options (From Unstoppable Prosperity) (Ad) Free NAVB Stock Alerts $0.04 0.00 (0.00%) (As of 05/3/2024 ET) Add Compare Share Share EarningsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueNAVB Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NAVB Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Allegiance GoldCould Your Accounts Be Frozen?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit NAVB Earnings Date and InformationNavidea Biopharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off prior year's report dates.Read More Get Navidea Biopharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for NAVB and its competitors with MarketBeat's FREE daily newsletter. Navidea Biopharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/9/2024Estimated)------- 11/14/2023Q3 2023-($0.02)($0.02)($0.02)--8/11/2023Q2 2023-($0.03)($0.03)($0.18)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)-- Get the Latest News and Ratings for NAVB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--Never use this word on your phone (FBI could be watching) (Ad)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...Watch my unredacted video about what I think is coming next right here11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--Charles Payne Demystifies Options (Ad)When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free.5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021($0.11)($0.08)+$0.03($0.08)$0.60 million$0.10 million 11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 millionCharles Payne Demystifies Options (Ad)When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free.8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/10/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million 5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/10/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million Navidea Biopharmaceuticals Earnings - Frequently Asked Questions When is Navidea Biopharmaceuticals's earnings date? Navidea Biopharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off last year's report dates. Learn more on NAVB's earnings history. How much revenue does Navidea Biopharmaceuticals generate each year? Navidea Biopharmaceuticals (NYSE:NAVB) has a recorded annual revenue of $70,000.00. How much profit does Navidea Biopharmaceuticals generate each year? Navidea Biopharmaceuticals (NYSE:NAVB) has a recorded net income of -$15.18 million. NAVB has generated -$0.06 earnings per share over the last four quarters. More Earnings Resources from MarketBeat Related Companies: MYMD Earnings Date BMRA Earnings Date TRIB Earnings Date IONM Earnings Date PHIO Earnings Date AEMD Earnings Date STSS Earnings Date NDRA Earnings Date CYCC Earnings Date GOVX Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Apple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings? This page (NYSE:NAVB) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsCharles Payne Demystifies OptionsUnstoppable ProsperityAutomatic Income (from home)Awesomely, LLCThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
